Madrigal Pharmaceuticals (MDGL) unusual spread trades 800 November $100 calls bought up to $9 and selling the September $90 calls at $2.25 for a bullish diagonal spread. A small $1B clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH). Expected to have Phase 3 NASH Biopsy Readout in 4Q of this year. IV highest in the November options saying any data results come before November but likely after September where the trader is selling the $90 calls.